Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT07670520

Conditions

Acute Kidney Injury

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Acute Kidney Injury in Care Transitions (ACT)

Usual Care

Study Details

Brief summary:

The purpose of this study is to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.

Conditions

Acute Kidney Injury

Study ID

NCT07670520

Start date

Apr 16, 2026

Status verified date

Jun, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Mar 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Clinician subjects

  • Hospital clinicians including physicians and advanced practice providers employed by Mayo Clinic and practicing at one of the four study sites
  • Provide care for hospitalized patients with stage 2 or stage 3 acute kidney injury (AKI) who are expected to be discharged home and are not receiving dialysis
  • Patient subjects:

  • Adults ≥18 years old
  • Meet KDIGO consensus criteria for stage 2 (moderate) or 3 (severe) AKI
  • Residence within the study catchment area (southern Minnesota, northern Iowa, or western Wisconsin)

Exclusion Criteria:

  • Clinician subjects: Physicians and advanced practice providers who:

  • Care exclusively for pediatric patients (<18 years)
  • Care exclusively for patients on palliative care
  • Patient subjects

  • Discharged to hospice care
  • Require outpatient dialysis at discharge
  • Are admitted from or expected to be discharged to a skilled nursing facility
  • Dementia Diagnosis
  • Have undergone solid organ transplant within the past 100 days
  • Decline authorization for use of their medical records for research

Study Design

Enrollment

2260 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Acute Kidney Injury in Care Transitions (ACT) Intervention

Physicians and nurse practitioners randomized to the ACT intervention group will be provided access to augmented kidney care support for acute kidney injury patients prior to hospital discharge, individualized according to post-discharge risk.

active comparator: Usual Care

Physicians and nurse practitioners randomized to the usual care group will provide standard of care education, labs, and clinical follow-up after discharge.

Interventions

Acute Kidney Injury in Care Transitions (ACT)

Clinicians will assign risk-individualized kidney health care prior to hospital discharge for acute kidney injury survivors. Low risk acute kidney injury survivors will receive education prior to hospital discharge, moderate risk acute kidney injury survivors will receive a referral to primary care for laboratory and clinical follow-up within approximately 14-days including a medication review by a pharmacist, and high risk acute kidney injury survivors will be referred to nephrologist-directed care including remote monitoring program (RPM) where available and aligned with the patients goals/values/preferences for up to 90 days after discharge for the highest risk patients.

Usual Care

Physicians and nurse practitioners will provide standard of care education, labs, and clinical follow-up after discharge.

Primary outcome measure

  • Hospital-Free Days [ Time Frame: 90 days, 180 days, 1 year ]

Central Contacts and Locations

Central contacts

Mitchell C. Strand

507-293-0952strand.mitchell@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Mitchell C. Strand

507-293-0952

Principal Investigator:

Erin F. Barreto, Pharm.D., Ph.D.

More Information

Sponsor

Mayo Clinic

Last update posted

Jun 26, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-06-26.